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Patients diagnosed with Neuroendocrine Tumors (NET) often are also diagnosed with Neuroendocrine Liver Metastases (NLM)
during the course of their disease. NLM can cause signiﬁcant morbidity and mortality, oftentimes much more than compared to
patients with NET. Treatment options have been limited in the past, focusing on surgical resections, for which only a minority
of patients are candidates. However, developments of new treatment modalities have progressed rapidly and patients with NLM
now have signiﬁcantly more options, including surgical-directed therapies; liver-directed therapies; and nonsurgical, non-liver-
directedtherapies.Thisreviewprovidesinformationabouttherolesofhepaticresection,orthotopicliverresection,radiofrequency
ablation, hepatic artery embolization and hepatic artery chemoembolization, hepatic artery radioembolization and selective
internal radiation therapy, peptide receptor radionuclide therapy, systemic chemotherapy, biotherapies including somatostatin
analogs and interferon-α, vascular endothelial growth factor and mTOR targets, and microRNA-regulated pathways. Given these
newoptions,thecliniciancantailortherapyspeciﬁctothepatientdiagnosedwithNLM,therebygivingthepatientthebestpossible
chance of prolonged survival.
1.Introduction
Patients with Neuroendocrine Tumors (NETs) often suﬀer
from Neuroendocrine Liver Metastases (NLMs) causing
signiﬁcant morbidity and mortality. The excess hormone
production, the multitude of hepatic lesions, and ultimate
liver disease lend to the poorer prognosis. In fact, 46%–93%
of patients with NETs will ﬁnd NLMs involved at the time
of diagnosis [1]. Patients with liver metastases have a signiﬁ-
cantly worse prognosis than those without liver involvement.
The5-yearsurvivalofpatientswithNLMsonsupportivecare
is 0%–20% [1–3]. This dismal prognosis paints a much more
stark reality for a pathological process often described as
“indolent”.SurgicalinterventionsforNLMshaveconsistently
been shown to have superior outcomes to nonoperative
therapies. Resection alone is supported by favorable long-
term outcomes in large retrospective trials [2]; however,
complete surgical extirpation is an option for a very small
percentage of the neuroendocrine cancer patient population
[1]. Due to excessive metastatic tumor burden in diﬃcult
locations, surgical resections are limited to only 10% of these
patients [2]. Treatment options for patients that are not
surgical candidates have evolved over the last several years.
Use of ablative techniques, as well as development of new
medical therapies, has expanded the treatment options for
the majority of patients with NLMs.
2.Surgical-DirectedTherapies
Surgery remains the only potential for cure in patients with
NLMs. Even in the setting of incurable disease, surgery oﬀers
the best chance for prolonged survival. In patients treated
with resection, the ﬁve-year survival has been shown to
be greater than 60% [4, 5] and even approaches 80% in
some studies, with minimal mortality (<5%) and morbidity
(<30%) [6]. A precise review of the literature available on
patients who undergo liver resection for neuroendocrine2 International Journal of Hepatology
tumors is diﬃcult due to the small number of patients
who are candidates and the varied approaches to surgical
treatment [7]. Historically, patients were selected to undergo
palliative resection if greater that 90% of the tumor burden
could be excised [8]. One of the earlier prospective studies
concluded from their study of 47 patients that hepatic
resection is indicated only when all gross disease can be
removed safely. In this study, they determined that number,
size, and location of primary tumor were less important
than the completeness of resection. Patients that underwent
a complete resection had a 5-year survival of 80%. However,
the patients that underwent an R1 resection had a 5-year
survival of 70% and R2 resection still had a 5-year survival
of 60%. Although patients in this study were included only if
it appeared that they could be completely resected, patients
that had incomplete resection still did well [9]. Several other
series have reported similar results [4, 6]. A more recent
retrospective review of 74 cases demonstrated a greater than
60% 5-year survival in all patients that underwent resection
[10]. Only 65% of these patients had all gross disease
completely excised.
Althoughanaggressivesurgicalapproachisconsideredto
prolong survival and contribute to better symptom control,
the criteria for patient selection are ill deﬁned. In an eﬀort to
identify variables that have prognostic relevance to patients
who undergo hepatic resection, a prospective review of 70
patients’ outcomes was performed based on tumor grade.
T h et u m o r sw e r ec a t e g o r i z e da sl o wg r a d e( <2 mitotic
ﬁgures/50hpf and no necrosis), intermediate grade (2–50
mitotic ﬁgures/50hpf and/or focal necrosis), and high grade
(>50 mitotic ﬁgures/50hpf and/or extensive necrosis). The
majority of the neoplasms were considered low grade (37)
or intermediate grade (26). Only 7 were shown to be high
grade. The overall 5-year survival rate was 61%. None of the
patients with high-grade malignancy survived 5 years with
a median survival of only 6 months [7]. The importance of
tumor grade to patient’s outcomes after resection has been
conﬁrmed by several investigations [10, 11].
Tumor size, number, and location have also been shown
to inﬂuence postresection survival [4, 12]. In 2008, the
ENETS proposed guideline for surgical resection based on
the 3 distinct patterns of liver involvement: (1) “simple”
pattern of metastasis located in one or two contiguous lobes
(20–25%), (2) “complex” pattern where there is one major
focusandotherlesionsarecontainedinthecontralaterallobe
(10–15%), and (3) “diﬀuse” disease in both lobes (60–70%)
[13]. The type of surgical resection is based on the patient’s
overall medical condition, size, number, and location of
lesions, and adequacy of remnant liver size/function. In
patients with the simple pattern of disease, an anatomic
resection is adequate to completely resect all disease. Patients
with the complex pattern of disease can be treated with
several diﬀerent methods. An anatomic lobectomy can be
performed for the majority of the disease and either a wedge
resection or locally ablative therapy can treat the remainder
of the tumors. Staged, multiple surgical procedures have also
been shown to be beneﬁcial with little increase in morbidity
and mortality [13].
The majority of patients with “diﬀuse” disease are
not candidates for resection. Cytoreductive surgery can be
helpful for a small, select group of patients. It is usually
recommended only in cases where >90% of the tumor
volume can be excised or in very young patients [12]. In
patients that are symptomatic, cytoreductive surgery has
been shown to improve or alleviate their symptoms for a
prolonged period of time. In addition, tumor debulking may
also increase the eﬀectiveness of medical therapy.
It has been estimated that less than 20% of patients
with metastatic neuroendocrine tumors are candidates for
hepatic resection [14]. Resection is not a viable option
for the majority of patients with diﬀuse hepatic disease.
Based on their slow growth and good response to resection,
liver transplantation has been tried in an attempt to cure,
prolong survival or control symptoms. Although many
centers are reluctant to allocate liver allografts to patients
with metastatic disease, liver transplantation for neuroen-
docrine tumors is one of the only accepted indications
for transplant in the setting of metastatic disease. In 1998,
Lehnert analyzed a total of 103 patients transplanted for
metastatic neuroendocrine carcinoma. The overall 5-year
survival was 47%, and disease-free survival was 24%. Tumor
histology or location of primary did not appear to eﬀect
survival in this study. However, extent of surgery at the time
of transplantation and age of recipient were signiﬁcant prog-
nostic factors for survival [15] .Am o r er e c e n tr e t r o s p e c t i v e
studywasperformedin2008.85patientswereidentiﬁedwho
underwent OLT for metastatic neuroendocrine carcinoma in
France. The overall 5-year survival was comparable at 47%
and disease-free survival of 20% at 5 years. In this study,
primary tumor location in the duodenum or pancreas was
noted to be an indicator of poor prognosis [16]. This ﬁnding
was not supported in several other investigations [2, 17].
One of the larger single center studies attempted to analyze
tumor biology in relation to postliver transplant outcomes.
These authors studied Ki-67, E-Cadherin, and p53. Based
on evaluation of 19 cases, they demonstrated that patients
with a low Ki-67 (<5%) and normal E-Cadherin staining
did signiﬁcantly better than patients with high Ki-67 or
abnormal E-Cadherin expression. Expression of p53 did not
appear to inﬂuence survival [18].
Analysis of the United Network for Organ Sharing
database reveals that between November 1988 and March
2011, only 185 liver transplants were performed for
metastatic neuroendocrine tumors in the United States.
The overall 5-year survival was 57.8%. This is signiﬁcantly
worse than the 74% 5-year survival for all other patients.
Although the long-term survival is not comparable to other
patients with benign disease, most liver transplant programs
will consider evaluating patients with NLMs. Many liver
transplant programs will consider a patient with metastatic
neuroendocrine for liver transplantation if the following
criteria are met:
(1) not a resection candidate,
(2) identiﬁcation and complete resection of primary
malignancy at least one year prior to evaluation,International Journal of Hepatology 3
(3) no evidence of extrahepatic disease demonstrated on
cross-sectional imaging or nuclear medicine scan,
(4) evidence of stability of disease for at least one year,
(5) failure of nonoperative treatments.
Liver transplantation for metastatic neuroendocrine
tumors remains controversial. This radical treatment occa-
sionally provides a cure, but the long-term survival is still
signiﬁcantly less than in patients transplanted for other
diseases. It can prolong survival and provide symptomatic
relief in a very small subset of patients. Patients that are
younger than 50 years in the setting of low Ki-67 and E-
Cadherin expression with symptoms that are diﬃcult to
controlappeartobeneﬁtthemostfromlivertransplantation.
3. Liver-DirectedTherapies
NETs are predisposed to form highly vascular metastatic
lesions in the liver and derive more than 90% of their
oxygenation and nutrition from the hepatic artery. Thus, the
hepatic artery oﬀers a viable mode of introducing directed
chemotherapy and/or creating an ischemic environment.
This eﬀectively starves the tumors of their nutrient and
oxygen supply while sparing healthy hepatic cells, which
derive the majority of their nutrient and oxygen supply from
the portal venous system. Several ablative techniques have
been developed that exploit the dual blood supply of the liver
in an eﬀort to control the disease process.
Deﬁning the treatment best suited for the tumor load
is dependent on number and location of the lesions,
invasiveness and size of the tumor, physiology and eﬀects of
hormone secretion, and extent of metastatic disease within
the patient. This is in conjunction with the ultimate goals of
cure or palliation. Considering the rate of recurrence, liver-
directed therapies have been considered more as debulking
modalities. In a review of the literature, general guidelines
for the treatment pathways are: for fewer nodular liver
metastatic lesions, local resection or thermal ablation is
recommended; for a higher-tumor load due to unresectable
multinodular disease or recurrent disease after resection,
hepatic artery embolization, hepatic artery chemoemboliza-
tion, or radioembolization is warranted [19]. These modal-
ities are also useful as “neoadjuvants” to decrease the size
of previously unresectable metastatic disease. Unless 80%–
90% of the tumor load is debulked, treatment does not serve
useful as palliation therapy to prolong survival and improve
symptom control [20].
3.1. Radiofrequency Ablation. Radiofrequency ablation
(RFA) uses an image-guided technique, percutaneous, lapar-
oscopic, or open, to provide local control with short-term
symptomatic relief [21] by subjecting tumors to intense,
destructive heat using an alternating electric current. This
technique is amenable to patients with fewer liver metastases
who are ineligible for hepatic resection. It is used as a single
modality, often more than once, or as an adjunct to other
NLMs therapies for debulking.
The largest study to date, with the longest followup, was
done at the Cleveland Clinic [21], a prospective trial of 89
patients with NLMs who underwent 119 laparoscopic RFA
sessions in total. Ninety-seven percent of the sample imme-
diately felt improvement of symptoms after the procedure,
where median disease-free survival was 1.3 years and overall
survivalat6yearsafterRFA[21].Ofnote,22%ofthissample
developedlocalrecurrence,with63%developingnewlesions
and 59% developing extrahepatic disease.
Prior to that study, Mazzaglia et al. investigated a series
of 63 patients who had a total of 452 treated NLMs lesions.
Symptoms were controlled an average of 11 ± 2.3 months
after RFA, with greater than 90% of symptomatic patients
experiencing relief immediately after procedure. Mean sur-
vival extended 3.9 years after the ﬁrst RFA treatment. Larger
dominant tumor size (>3cm) and male sex were signiﬁcant
v a r i a b l e sn e g a t i v e l yc o r r e l a t e dw i t hs u r v i v a l[ 22].
A United Kingdom group describes RFA of 189 lesions
in 25 patients. Median survival of the group was 53 months
from liver diagnosis. Of those with radiologic followup, 74%
ofpatientswerenotedtohavetumorloadcontrolatamedian
of 21 months after the procedure. This meant complete, par-
tial, or static tumor response to RFA. Hormonal treatment
has also been used as an adjunct to improve symptomatic
relief, though not improve survival. Adjuvant octreotide has
been shown to extend median symptom-free duration from
16 to 60 months [19] .I th a sn o t ,h o w e v e r ,b e e np r o v e nt o
increase survival.
Morbidity for radiofrequency ablation of liver metastases
has been reported in the larger studies to be approximately
5% to 12%, with 30-day mortality at 0% to 1%. [21, 22]T h e
complications can include carcinoid crisis, liver abscesses,
biliopleural ﬁstulas, bile leakage, and pleural eﬀusion, as well
as postablation syndrome, and liver failure.
3.2. Hepatic Artery Embolization and Hepatic Artery Che-
moembolization. Capitalizing on the dual blood supply of
the liver enables a transarterial approach to the hepatic
lesionsofneuroendocrinemetastases.Hepaticarteryemboli-
zation (HAE) induces ischemia within the tumor, using a
variety of agents such as cyanoacrylate, gel foam particles,
polyvinyl alcohol, and microspheres. Indications for HAE
or hepatic artery chemoembolization (HACE) generally
include unresectability with symptoms related to tumor
bulk, excessive hormone production, and rapid progression
of liver disease [3]. HAE has been shown to improve
biophysical markers, palliate symptoms and reduce tumor
burden by radiographic evaluation [2, 23]. Because of the
observation that higher disease regression rate and longer
length of regression with systemic chemotherapy after HAE
was published [24], chemotherapy has been added to the
embolic agents, and HACE is now generally favored over
HAE. HACE, also known as transarterial chemoemboliza-
tion, combines the hepatic artery embolization with the
hepatic artery chemoinfusion where the microspheres are
bound to chemotherapy agents, which are then injected into
the hepatic artery to lodge downstream within capillaries.
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ischemic necrosis, but the chemotherapy agents are localized
within the region of the metastatic lesions, creating a much
more concentrated eﬀect (up to 20 times greater) than
systemic chemotherapy alone [22] as well. Despite this theo-
retical advantage, little evidence has suggested a signiﬁcant
diﬀerence in the outcomes of hepatic artery embolization
versus hepatic artery chemoembolization. In a review of the
literature, HACE has shown a 5-year survival between 50%
to 65% whereas HAE has a 5-year survival between 40%
to 67% [24]. In one study of 100 patients with NLMs who
received HACE or HAE, the authors found no diﬀerence in
overall survival, median survival after diagnosis of metastatic
disease, or median survival after ﬁrst embolization [25].
On univariate analysis, the only predictor that signiﬁcantly
improved survival was concurrent resection of the primary
tumor, which increased median survival from 28.0 months
to 73.1 months [25]. Contrary to this study, Ho et al.
reported results on 46 patients with NLMs who received
HACE or HAE, and showed that there was no statistically
signiﬁcant survival beneﬁt in a small subset of population
that also had resection of the primary tumor, although mean
survival after resection increased by a mean of 558 days
[26]. Regardless, these therapies have increased versatility
as reﬂected in a study of 48 patients and 123 treatment
sessions which revealed HACE or HAE could even beneﬁt
carefully selected patients with a tumor load of greater than
75% liver involvement, so long as the patients did not have
additional risk factors [27]. Having said this, a number of
reports reveal worse outcomes for patients with greater than
50% liver involvement [28, 29]. This is tempered by the
fact that extent of liver involvement did not serve as an
independent prognostic indicator [3]. In order to mediate
the complications arising from disease which takes up the
bulk of the liver, it is recommended to divvy small portions
of the liver for treatment during each session.
There are adjuvants to HACE or HAE in those patients
with severely limited therapeutic options to improve oth-
erwise bleak outcomes, and HACE or HAE can be used
as adjuvant therapy to other treatments. Adding hepatic
artery chemoinfusion (HAI) to HACE oﬀers an increased
probability of clinical beneﬁts to those with unresectable,
refractory disease, as presented in a study of 77 patients [30].
Theresponseratewas80%ofisletandcarcinoidtumorswith
a median progression-free survival of 19 months. 1- and 5-
year survival rates were 78% and 27% [31]. Of the diﬀerent
types of neuroendocrine tumors, carcinoid tumors seem to
consistently have better outcomes to the combination of
HACE and HAI [21, 23, 30]. Although studies on patients
with NLMs are limited, in one study of 32 patients with
hepatocellular carcinoma, the authors found that there was
no survival advantage in patients with preoperative HACE
prior to surgical resection [32]. In fact, the recurrence-
free survival rates were statistically higher, and cumulative
recurrence rates were statistically lower at 1, 2, and 5 years
compared between the two groups [32]. One study from
IowaonpatientswithNLMsshowedthatpreoperativeHACE
followed by OLT can result favorably for the patients with
progression-free intervals up to 29 months, but this was a
small study, and statistical inferences could not be made due
to the inclusion of only four patients [33]. Along a diﬀerent
treatment strategy, Hao et al. showed that survival improved
when patients with hepatocellular carcinoma received com-
bination therapy with HACE plus thalidomide versus HACE
alone[34].Thisimprovementreachedstatisticallysigniﬁcant
improvement, resulting in median overall survival increases
of 15 months [34]. Similarly, in an experimental model
utilizinglivertumorsinrabbits,favorableoutcomesresulting
in signiﬁcantly decreased vascular endothelial growth factor
and microvascular density levels were achieved when HACE
plus antiangiogenic therapies were used [35]. However,
tumor size was not signiﬁcantly diﬀerent between these two
groups [35].
AnimportantpointofHACEorHAEisthatresponsecan
be incomplete as the periphery of the tumor is spared from
ischemia or chemotherapy. With proximal embolization of
arterial branches feeding the tumors, peripheral hepatic
collaterals reconstitute quickly, requiring repeated emboliza-
tions to complete the necrotic process [24]. Multiple sessions
are usually needed.
As all other procedures, there are risks involved
with liver-directed therapy through the hepatic artery.
Liver abscesses, transient liver failure with or without
encephalopathy, carcinoid crisis, pleural eﬀusions, and
postembolization syndrome (i.e., fever, abdominal pain,
leukocytosis, and transient increases in hepatic enzymes and
bilirubin) are some of the more common and worrisome.
Relativecontraindicationsfortheseproceduresincludecoag-
ulopathy,renalfailure,portalveinocclusion,andliverfailure.
3.3. Hepatic Artery Radioembolization and Selective Internal
Radiation Therapy. Limited eﬀective strategies exist for the
treatment of inoperable, refractory NLMs. Interest in one
particular liver-directed therapy is under further investiga-
tion for this indication: hepatic artery embolization (HAR),
also known as selective internal radiation therapy (SIRT).
SIRTactsbydeliveringmicrospheresofglassorresin,labeled
by 90Yttrium (90Y) to deliver radiation directly into the
hepatic artery. Rather than using peptides to localize the
lesions, this therapy mechanically targets the metastases
and lodges within the nutrient-supplying capillaries, thereby
delivering radiation therapy. While this modality has been
tested in a limited number of NETs patients, the results thus
far have shown promise [31, 36–38].
Saxena et al. have been investigating the safety and
eﬃcacy of treatment with 90Y radioactive microspheres
for patients with unresectable NLMs. In this study, 34
such patients were treated with SIRT to achieve long-term
responses with a mean overall survival of 29.4 ± 3.4 months,
and radiological improvement in 50%. Biochemical marker
levels of chromogranin A fell in nearly 50% of survivors by
30 months [31].
InonemulticenterretrospectivereviewbyKennedyetal.,
148 patients with NLMs were followed after radioemboliza-
tion with 90Y[ 38]. This study reports favorable results with
radiological response in 63.2% of patients, stable disease in
22.7%, and progression of disease in only 4.9% [38]. The
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is the stabilization of extensive disease allowing for longer
survival periods [38].
Another recent publication investigated 48 patients who
underwent similar treatment [37]. Radiographic and serol-
ogy studies revealed median survival of 35 months with a
followup of 41 months, and 55% of patients had complete or
partial responses [37]. Less than a quarter of the sample had
progressive disease [37]. Prognostic factors were assessed,
and 6 of signiﬁcance were found to inﬂuence survivorship:
complete/partialresponse,lowhepatictumorburden,female
gender, well-diﬀerentiated tumors, and absence of extrahep-
atic metastases [37]. This was important in identifying a
subset of the NLMs patient population who would be best
served by this newer technique.
The complications of radioembolization include abdom-
inal pain, nausea, and fever. Radiation gastritis and duodenal
ulcershavebeendescribed,andasallliver-directedtherapies,
the risk of liver failure is present. Of note, this promising
modality of care, while approved for treatment of colonic
cancer metastases to the liver, is still under FDA investigation
for treatment of NLMs. Current literature suggests there
is signiﬁcant potential in SIRT/HAR as part of the arma-
mentarium against neuroendocrine tumors and its hepatic
metastases.
4.Nonsurgical,Non-Liver-DirectedTherapies
Since NLMs is a rare disease, large-scale, randomized trials
prove diﬃcult, and although these therapies have been used
in the treatment of NETs, not all have been speciﬁcally used
in the treatment of NLMs. Due to the multiple therapies
available, the eﬀectiveness of one versus another is diﬃcult
to study, and many times nonsurgical, non-liver-directed
therapies tend to be lumped together in studies that are
available.Moreover, therecontinues to be alackof consensus
on a nonsurgical treatment algorithm; however, most agree
that nonsurgical, non-liver-directed treatments of NETs and
NLMs constitute palliative care. At least, one single-center
studyinthemedicalliterature[12]hasproventhataggressive
treatment of NLMs with nonsurgical therapy can extend 3-
and 5-year survival rates in patients to 76.4% and 63.9% as
compared to previously stated survival rates of 39% [14]a n d
25% [39], respectively. With these encouraging results and
the boom in treatment advancements, the older perspective
of “wait-and-watch” treatment is considered antiquated.
4.1. Peptide Receptor Radionuclide Therapy. Peptide receptor
radionuclide therapy (PRRT) is an upcoming option with
enticing advantages, most useful in symptomatic patients
with somatostatin receptor-positive tumors, who are not
surgical candidates. Between 80% to 95% of gastroen-
teropancreatic, NETs express somatostatin receptors [40]
as demonstrated by 111In-pentetreotide scans (OctreoScan,
Covidien-Mallinckrodt Imaging, Hazelwood, MO 63042)
[41], so PRRT may be useful for a large percentage of NLMs,
perhaps in up to 25% of patients [12]. PRRT utilizes the
targeting of a molecule to speciﬁc receptors located on the
surface of tumor cells. Once the molecule interacts with
the receptor, it is internalized, thereby delivering speciﬁc
and localized radiotherapy. This technique allows precise
destruction of tumor cells [42, 43], with little interference of
nontumor tissue, except for some exposure of renal, bladder,
and bone marrow tissues [44]. 90Y, 177Lutetium (177Lu), or
111Indium (111In) are radionuclides that are linked with a
somatostatin analog: octreotide, octreotate, or lanreotide.
The more the tumor expresses somatostatin receptors as
compared to the surrounding tissue, the more eﬀective the
PRRT will be. Somatostatin scintigraphy can predict the
eﬀectiveness of PRRT: low uptake indicates 20% chance of
eﬀect on liver metastases, whereas high uptake indicates a
60% chance [45]. 177Lu-DOTA0Tyr3octreotate seems to be
the most eﬀective PRRT, with a tumor response rate of
35% and tumor stabilization of 80% to 90% of NETs [44],
versus 90Y-DOTA0Tyr3octreotide with a tumor response of
4% and tumor stabilization of 70% [46]. After therapy with
90Y-DOTA0Tyr3octreotide or 177Lu-DOTA0Tyr3octreotate,
median duration of results were 30 months and 36 months,
respectively [45]. In one study with 310 patients, median
overall survival rate from initiation of PRRT was 46 months
[47]. Further, patients experiencing beneﬁt after one round
of PRRT who develop recurrent or progressive disease may
beneﬁt from a second round of PRRT [48].
Side eﬀects of PRRT are rare and usually mild consisting
most commonly of nausea and vomiting occurring within
24 hours of administration [41], and although anemia and
transient toxicity grade 1 have been reported [12], long-
lasting adverse side eﬀects are extremely rare. Patients that
seem to beneﬁt the most from PRRT have strong radio-
tracer uptake on OctreoScan, at least as much as the liver
[41]. Newer positron emission tomography (PET) imaging
p l a t f o rm ss u c ha s68Gallium-DOTA0Tyr3octreotide-PET and
68Gallium-DOTA0Tyr3octreotate-PET are increasingly used
to evaluate tumors as they are even more sensitive to
radiotracer uptake [40] and may be able to better predict
responsiveness to PRRT [49]. Unfortunately, PRRT is not
available in the United States until September 2011, when
the ﬁrst clinical trial will begin (http://clinicaltrials.gov/;
Identiﬁer: NCT01237457).
4.2. Chemotherapy. The use of systemic chemotherapy is less
clear in the treatment of NLMs. Several chemotherapeutic
agents have been used in multiple trials, but mainly in the
study of NETs only, with limited success and restrictions
from side eﬀects and toxicities.
The usefulness of chemotherapy in the treatment of
NETs seems to be related to primary tumor location
and tumor grade [41]. Pancreatic NETs have been treated
successfully with nitrosurea streptozocin (STZ) [41]. The
greatest eﬃcacy seems to be related to the use of STZ
with other chemotherapy agents, including 5-ﬂuorouracil
and doxorubicin, but still only results in a median response
time of 9.3 months [50]. Dacarbazine (DTIC) is another
chemotherapy agent with proven eﬀectiveness in pancreatic
NETs, and in one phase II trial demonstrated a response rate
of 34% [51]. The alkylating agent, temozolomide, has also
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temozolomide and thalidomide showed a response rate of
45% [52], and a retrospective study of temozolomide and
capecitabine showed a response rate of 70%, a median PFS
of 18 months, and an overall 2-year survival of 92% [53].
Platinum-based chemotherapy regimens may be useful in
patients with high-grade, poorly diﬀerentiated NETs, with
response rates of 42% to 80% with the use of cisplatin and
etoposide [54–56], and 78% with use of oxaliplatin-based
regimens [57]. Even with increased response rates, median
survival times are of short duration of 8 to 11 months [56].
Therefore, chemotherapy can be used as salvage treatment,
but is generally not considered as ﬁrst-line, nonsurgical
treatment.Moreover,thepresenceofNLMsmayberelatedto
worse response to chemotherapy as compared to NETs [58].
4.3. Biotherapy
4.3.1. Somatostatin Analogs. Somatostatin exerts its aﬀect by
integration with one of ﬁve somatostatin receptors, ssts1−5
[59], but due to a half-life of only two minutes [60],
somatostatin analogs (SSA) have been developed. Newer
formulationsmaybeeveneasiertoadministertopatientsdue
to a longer half-life of approximately two hours [61].
The principle use of SSA is in the symptomatic relief
of NETs and NLMs, although it may be useful for other
indications. The use of SSA produces a median biochemical
response rate between 0% to 77%; and biochemical and
radiographic tumor stability of 28% and 55%, respectively
[61–71]. One review article found symptomatic and tumor
response to octreotide, octreotide long-acting repeatable
(LAR), lanreotide, and lanreotide slow-release depot (auto-
gel) in 74.2%, 77.3%, 63.0%, and 67.5%, and in 57.4%,
69.8%, 46.6%, and 64.4%, respectively [72]. Another inves-
tigation demonstrated relief from ﬂushing and diarrhea in
88% of patients after octreotide administration [61]. Interim
data from the PROMID study with metastatic midgut NETs,
showed a 66% reduction in the risk of disease progression
and arrested tumor growth in 69% for a median of 14.3
months[73].However,over75%ofpatientsinthisstudyhad
limited liver involvement of 10% or less, and the response
was highest in patients with relatively low tumor burden
[73]. The greatest response rates have been witnessed with
octreotide doses of 30mg/day or greater or with lanreotide
doses of 5mg/day or greater [74]; octreotide doses greater
than 60mg/day likely do not have additive eﬀect due to
oversaturation of receptor sites [75]. Similar to PRRT, the
level of uptake on somatostatin scintigraphy may be an
indicator of patient’s response to SSA therapy [44].
The newest SSA, pasireotide, is still in clinical develop-
ment stages, but is promising due to binding of ssts1, ssts2,
ssts3,andssts5 [41],ascomparedtooctreotideandlanreotide
which bind to ssts2 and ssts5 only. Preliminary data indicate
that pasireotide may be useful in patients with symptoms
refractorytooctreotide,possiblycontrollingsymptomsinup
to 27% of these patients [76].
Side eﬀects are infrequent, but nausea, stomach cramp-
ing or discomfort, diarrhea, steatorrhea, cardiac abnormal-
ities and arrhythmias, hypothyroidism, and hypoglycemia
may occur [40, 41, 77]. Cholelithiasis may arise in up to
50% of patients due to inhibition of gallbladder contractility
[41], but only a handful will develop symptoms requiring
cholecystectomy [78].
4.3.2. Interferon-α. Interferons have multiple antitumor
eﬀects [79], and they may upregulate somatostatin receptors
in NETs [80], thereby providing a useful combination thera-
peuticoption.Interferon-αcanamelioratesymptomsin30%
to 70% of patients [81, 82] ,a n di ns o m es t u d i e sh a ss h o w n
promising results with tumor response rate or stabilization
in up to 70% of patients [82]. However, the results of
three randomized clinical trials involving interferon-α and
octreotide have mixed results. Two demonstrated increased
5-yearsurvivalrate[70]andmediansurvivaltime[83]inthe
combination group versus the octreotide-only group, 57%
versus 37% and 51 months versus 35 months, respectively;
but another trial showed minimal response rates [84].
The side eﬀect proﬁle of interferons may preclude wide
utilization. Interferon-α can cause fevers, chills, myalgias,
depression, and myelosuppression [41], and is considered
inferior to SSA. However, in patients with progressive
disease, combination therapy may be a viable option [85].
Others have examined the role of dopamine receptors
and interferon-β [86] as other possible targets, but currently,
neither of these targets seems promising at this time due to
ineﬀectiveness and short half-life.
4.4. Newer Therapies. Patients who have exhausted other
therapies may ﬁnd acceptable treatment through the use of
newertreatmentstrategies.Theseinterventionsremaininthe
investigativeprocess,includingtargetingvascularendothelial
growth factors (VEGF), mTOR pathways, other growth
factor receptors, antiproliferative factors, and antiangiogenic
factors. Monoclonal antibodies against insulin-like growth
factor-1 receptor (IGF-1R): AMG479, IMC-A12, and MK-
0646, are currently in clinical phase II studies in patients
with metastatic NETs (http://clinicaltrials.gov/, identiﬁer:
NCT01024387, NCT00781911, NCT00610129). Others are
looking at genetic copy number alterations of tumor sup-
pressor genes [87] and the detection and characterization of
circulating tumor cells to reduce metastatic burden [88]a s
other possible avenues to treat NETs and NLMs.
4.4.1. Targeting Vascular Endothelial Growth Factors. NETs
and NLMs frequently overexpress the vascular endothelial
growth factor (VEGF) ligand and receptor (VEGFR) [89].
Tumor progression of NETs has also been associated with
circulating levels of VEGF [41], therefore VEGF and VEGFR
are promising targets.
In a study where patients on octreotide therapy
were randomized into either treatment with bevacizumab,
a humanized monoclonal antibody against VEGF, or
interferon-α, 95% of patients receiving bevacizumab were
progression-free after 18 weeks, compared to 67% of
patients receiving interferon-α [36]. Bevacizumab is asso-
ciated with reduction of tumor blood ﬂow and longerInternational Journal of Hepatology 7
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Figure 1: Algorithm for treatment of neuroendocrine liver metastases. The preferred treatment options involve surgical management,
followed by liver-directed therapies, or a combination of these procedures. Nonsurgical, non-liver-directed therapies constitute palliative
care.
progression-free survival (PFS) when compared to alter-
native treatments [36]. Currently, multiple clinical tri-
als of bevacizumab are ongoing (http://clinicaltrials.gov/,
identiﬁers: NCT00569127, NCT00137774, NCT00398320,
NCT00227617, NCT00607113). Bevacizumab may cause
hypertension and proteinuria [44], so optimal patient selec-
tion prior to treatment is mandatory.
Sunitinib is a tyrosine kinase receptor inhibitor cur-
rently approved in the treatment of renal cell carcinoma
and gastrointestinal stromal tumors and inhibits VEGFR1,
VEGFR2, and VEGFR3. Phase III trials resulted in median
PFS of 11.1 months for patients on sunitinib versus 5.5
months for patients receiving placebo (P < 0.001) [40, 90,
91]. In Europe, sunitinib is approved for the treatment
of unresectable or metastatic, well-diﬀerentiated pancreatic
NETs with disease progression in adults [40]. Side eﬀects
of sunitinib include fatigue, asthenia, diarrhea, nausea,
vomiting,anorexia,bleedingcomplications,mucosalinﬂam-
mation, hypertension, anemia, granulocytopenia, thrombo-
cytopenia, and hypothyroidism [40].
4.4.2. Targeting mTOR Pathway. The mammalian target
of rapamycin (mTOR) pathway is central to the control
of cell growth, protein synthesis, and apoptosis and is
activated in NETs [40]. Two mTOR inhibitors have been
developed and approved for use in renal cell carcinomas
[92],everolimus,andtemsirolimus,andhavebeenstudiedin
NETs [41, 93–95]. Everolimus has a potential in conjunction
with octreotide LAR [93] and as a monotherapeutic agent
with a response rate of 20%, a median PFS between 11
and 16 months in three separate phase III trials [41, 96],
and with stabilization of disease in 70% with low- to-
intermediate grade NETs [93]. Side eﬀects of everolimus
include stomatitis, rash, diarrhea, fatigue, infections, non-
infectious pneumonitis, anemia, lymphopenia, hypercholes-
terolemia, hyperlipidemia, and hyperglycemia [40].
4.5. MicroRNA-Regulated Pathways. MicroRNAs are small,
noncoding RNAs that can function as gene regulators
by posttranscriptional processes, such as inducing mRNA
degradation or repression of translation [97–100]. MicroR-
NAs are usually downregulated in cancers [97–100]a n d
have been studied for possible therapeutic interventions.
One study identiﬁed microRNA-133a, -145, -146, -222,
and -106 to be important in primary NETs, whereas
microRNA-183, -488, -19a+b were found to be important in
metastatic NETs [97]. Further, the same group determined
that decreasing levels of microRNA-133a has an important
roleinthedevelopment,progression,andpossiblemetastasis
of midgut carcinoid tumors [97]. A diﬀerent study identiﬁed
microRNA-142-3p, -142-5p, -155, -146a, and -483 as up-
regulated in pancreatic NETs as compared to normal tissue
[101]. This study also found that microRNA-210, -431, and
-424 were up-regulated in metastases as compared with
tumors, suggesting that certain microRNAs could be used
to predict the probability of metastasis [101]. Another study8 International Journal of Hepatology
showed that anti-microRNA-182 targeting had a therapeutic
eﬀect against melanoma liver metastasis, which may be
extended to other tumors [102].
Additional studies are warranted in this area pertaining
to microRNA-regulated pathways, but already possible ther-
apeutic targets have been identiﬁed by researchers including
the high-mobility group A proteins, HMGA1, HMGA2, and
the microRNA family let-7 [103, 104]. These targets will be
useful as better strategies evolve to care for patients with
NLMs and extend their survival.
5. Conclusion
The treatment modalities available to a patient diagnosed
with liver metastases due to NETs are vast. The options range
from surgical treatments, to locally liver-directed therapies,
to systemic approaches (Figure 1). However, most, if not
all clinicians, agree that the treatment must be tailored
speciﬁcally to the patient. Generally, surgical therapies are
preferred as they can give the longest disease-free interval.
Yet, not all patients with NLMs are candidates for surgical
therapy, and in the case of an elderly asymptomatic patient
with a slow-growing NETs, the patient may not desire
surgical therapy. Liver-directed treatment can also produce
great results, extending the lifetime of the patient without
riskier surgical interventions. Moreover, liver-directed ther-
apies may clearly beneﬁt a patient who is symptomatic from
their tumor or may even allow that patient to be a candidate
for surgical treatment in the future. Lastly, nonsurgical,
non-liver-directed therapies are considered palliative care in
the treatment of NLMs. These systemic therapies are not
ﬁrst line, but can still achieve longer lifespans as a salvage
therapy. Newer technologies, including genetic targets such
as microRNA subtypes, are fast evolving and will continue
to allow patients with NLMs several options. Even though
NETs are rare tumors, NLMs are even more rare, and this
characteristic prevents large, randomized-controlled trials
and modalities of treatment for these tumors continue to
improve as there is an obvious need. These treatments are
expected to maintain this progression well into the future,
especially as knowledge of NLMs increases with additional
studies, so that we may provide patients diagnosed with
NLMs with every possible chance towards increased survival.
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